Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisOngoing discussions with ...

Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...

Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...

Shares of Sanofi SNY fell nearly 2% on Monday after the company reported two setbacks in connection with its investigational ...

FDA has given tentative approval to Lupin’s Siponimod tablets, a bioequivalent version of Mayzent, to treat people with ...

Sanofi SA reported more hitches in the development of Bruton’s tyrosine kinase inhibitor tolebrutinib, saying the phase III Perseus study failed to meet its primary endpoint in primary progressive ...

that affects the central nervous system. There are various types of MS. Several of these are characterized by inflammation and damage due to demyelination and scarring in the central nervous system, ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...

In women with relapsing-remitting MS, a six-month gluten-free diet was found to ease disability and support a healthier body ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.